<!DOCTYPE html>
<html lang="en-GB" xmlns:og="http://ogp.me/ns#" xmlns:fb="http://ogp.me/ns/fb#">
<head >
<meta charset="UTF-8" />
<title>COMPare -   Lessons in Outcome Switching: The ERASE Trial</title>		<meta name="robots" content="noodp,noydir" />
		<meta name="viewport" content="width=device-width, initial-scale=1" />
<link rel='dns-prefetch' href='http://w.sharethis.com/' />
<link rel='dns-prefetch' href='http://fonts.googleapis.com/' />
<link rel="alternate" type="application/rss+xml" title="COMPare &raquo; Feed" href="../../../feed/index.html" />
<link rel="alternate" type="application/rss+xml" title="COMPare &raquo; Comments Feed" href="../../../comments/feed/index.html" />
<link rel="alternate" type="application/rss+xml" title="COMPare &raquo; Lessons in Outcome Switching: The ERASE Trial Comments Feed" href="feed/index.html" />
<link rel="canonical" href="index.html" />
<link rel='stylesheet' id='parallax-pro-theme-css'  href='../../../wp-content/themes/parallax-pro/style.css%3Fver=1.2.2.css' type='text/css' media='all' />
<link rel='stylesheet' id='sm-style-css'  href='../../../wp-content/plugins/wp-show-more/wpsm-style.css%3Fver=4.6.16.css' type='text/css' media='all' />
<link rel='stylesheet' id='kamn-css-easy-twitter-feed-widget-css'  href='../../../wp-content/plugins/easy-twitter-feed-widget/easy-twitter-feed-widget.css%3Fver=4.6.16.css' type='text/css' media='all' />
<link rel='stylesheet' id='dashicons-css'  href='../../../wp-includes/css/dashicons.min.css%3Fver=4.6.16.css' type='text/css' media='all' />
<link rel='stylesheet' id='parallax-google-fonts-css'  href='http://fonts.googleapis.com/css?family=Montserrat%7CSorts+Mill+Goudy&amp;ver=1.2.2' type='text/css' media='all' />
<link rel='stylesheet' id='sccss_style-css'  href='../../../index.css' type='text/css' media='all' />
<script type='text/javascript' src='../../../wp-includes/js/jquery/jquery.js%3Fver=1.12.4'></script>
<script type='text/javascript' src='../../../wp-includes/js/jquery/jquery-migrate.min.js%3Fver=1.4.1'></script>
<script type='text/javascript'>
/* <![CDATA[ */
var cssTarget = "img.";
/* ]]> */
</script>
<script type='text/javascript' src='../../../wp-content/plugins/svg-support/js/min/svg-inline-min.js%3Fver=1.0.0'></script>
<!--[if lt IE 9]>
<script type='text/javascript' src='http://compare-trials.org/wp-content/themes/genesis/lib/js/html5shiv.min.js?ver=3.7.3'></script>
<![endif]-->
<script type='text/javascript' src='../../../wp-content/themes/parallax-pro/js/responsive-menu.js%3Fver=1.0.0'></script>
<script id='st_insights_js' type='text/javascript' src='http://w.sharethis.com/button/st_insights.js?publisher=eba0f3ba-f9ab-408c-bc68-c28af5afe749&#038;product=feather'></script>
<link rel='https://api.w.org/' href='../../../wp-json/index.html' />
<link rel="EditURI" type="application/rsd+xml" title="RSD" href="../../../xmlrpc.php%3Frsd" />
<link rel="alternate" type="application/json+oembed" href="http://compare-trials.org/wp-json/oembed/1.0/embed?url=http%3A%2F%2Fcompare-trials.org%2Fblog%2Flessons%2Ferase" />
<link rel="alternate" type="text/xml+oembed" href="http://compare-trials.org/wp-json/oembed/1.0/embed?url=http%3A%2F%2Fcompare-trials.org%2Fblog%2Flessons%2Ferase&#038;format=xml" />
<style type='text/css'></style>

<style type="text/css"></style>

<style type="text/css">
.synved-social-resolution-single {
display: inline-block;
}
.synved-social-resolution-normal {
display: inline-block;
}
.synved-social-resolution-hidef {
display: none;
}

@media only screen and (min--moz-device-pixel-ratio: 2),
only screen and (-o-min-device-pixel-ratio: 2/1),
only screen and (-webkit-min-device-pixel-ratio: 2),
only screen and (min-device-pixel-ratio: 2),
only screen and (min-resolution: 2dppx),
only screen and (min-resolution: 192dpi) {
	.synved-social-resolution-normal {
	display: none;
	}
	.synved-social-resolution-hidef {
	display: inline-block;
	}
}
</style>
<link rel="icon" href="../../../wp-content/uploads/2016/01/cropped-original-32x32.png" sizes="32x32" />
<link rel="icon" href="../../../wp-content/uploads/2016/01/cropped-original-192x192.png" sizes="192x192" />
<link rel="apple-touch-icon-precomposed" href="../../../wp-content/uploads/2016/01/cropped-original-180x180.png" />
<meta name="msapplication-TileImage" content="http://compare-trials.org/wp-content/uploads/2016/01/cropped-original-270x270.png" />

<!-- BEGIN GADWP v4.9.3.2 Universal Tracking - https://deconf.com/google-analytics-dashboard-wordpress/ -->
<script>
  (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
  (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
  m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
  })(window,document,'script','//www.google-analytics.com/analytics.js','ga');
  ga('create', 'UA-70146570-1', 'auto');
  ga('send', 'pageview');
</script>

<!-- END GADWP Universal Tracking -->


<!-- START - Facebook Open Graph, Google+ and Twitter Card Tags 2.0.4 -->
 <!-- Facebook Open Graph -->
  <meta property="og:locale" content="en_GB"/>
  <meta property="og:site_name" content="COMPare"/>
  <meta property="og:title" content="Lessons in Outcome Switching: The ERASE Trial"/>
  <meta property="og:url" content="http://compare-trials.org/blog/lessons/erase"/>
  <meta property="og:type" content="article"/>
  <meta property="og:description" content="Over 6 weeks the COMPare team analysed 67 trials in the top 5 medical journals to assess the ongoing prevalence of outcome switching in clinical trials, and to find out why it persists. Our methodology can be found here. In this series we will be highlighting the salient lessons learned from this pr"/>
  <meta property="og:image" content="http://compare-trials.org/wp-content/uploads/2016/01/logo_large-1.png"/>
  <meta property="article:published_time" content="2016-03-22T22:52:20+00:00"/>
  <meta property="article:modified_time" content="2016-06-12T13:44:29+00:00" />
  <meta property="og:updated_time" content="2016-06-12T13:44:29+00:00" />
  <meta property="article:section" content="Uncategorized"/>
 <!-- Google+ / Schema.org -->
  <meta itemprop="name" content="Lessons in Outcome Switching: The ERASE Trial"/>
  <meta itemprop="description" content="Over 6 weeks the COMPare team analysed 67 trials in the top 5 medical journals to assess the ongoing prevalence of outcome switching in clinical trials, and to find out why it persists. Our methodology can be found here. In this series we will be highlighting the salient lessons learned from this pr"/>
  <meta itemprop="image" content="http://compare-trials.org/wp-content/uploads/2016/01/logo_large-1.png"/>
 <!-- Twitter Cards -->
  <meta name="twitter:title" content="Lessons in Outcome Switching: The ERASE Trial"/>
  <meta name="twitter:url" content="http://compare-trials.org/blog/lessons/erase"/>
  <meta name="twitter:description" content="Over 6 weeks the COMPare team analysed 67 trials in the top 5 medical journals to assess the ongoing prevalence of outcome switching in clinical trials, and to find out why it persists. Our methodology can be found here. In this series we will be highlighting the salient lessons learned from this pr"/>
  <meta name="twitter:image" content="http://compare-trials.org/wp-content/uploads/2016/01/logo_large-1.png"/>
  <meta name="twitter:card" content="summary"/>
  <meta name="twitter:site" content="@compare_trials"/>
 <!-- SEO -->
  <meta name="description" content="Over 6 weeks the COMPare team analysed 67 trials in the top 5 medical journals to assess the ongoing prevalence of outcome switching in clinical trials, and to find out why it persists. Our methodology can be found here. In this series we will be highlighting the salient lessons learned from this pr"/>
 <!-- Misc. tags -->
<!-- END - Facebook Open Graph, Google+ and Twitter Card Tags 2.0.4 -->

</head>
<body class="single single-post postid-355 single-format-standard full-width-content" itemscope itemtype="http://schema.org/WebPage"><div class="site-container"><header class="site-header" itemscope itemtype="http://schema.org/WPHeader"><div class="wrap"><div class="title-area"><h1 class="site-title" itemprop="headline"><a href="../../../index.html">COMPare</a></h1><h2 class="site-description" itemprop="description">Tracking switched outcomes in clinical trials</h2></div><div class="widget-area header-widget-area"><section id="nav_menu-3" class="widget widget_nav_menu"><div class="widget-wrap"><nav class="nav-header" itemscope itemtype="http://schema.org/SiteNavigationElement"><ul id="menu-main-menu" class="menu genesis-nav-menu"><li id="menu-item-14" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-14"><a href="../../../project.html" itemprop="url"><span itemprop="name">Methods</span></a></li>
<li id="menu-item-15" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-15"><a href="../../../results.html" itemprop="url"><span itemprop="name">Results</span></a></li>
<li id="menu-item-13" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-13"><a href="../../../team.html" itemprop="url"><span itemprop="name">Team</span></a>
<ul class="sub-menu">
	<li id="menu-item-633" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-633"><a href="../../../speaking.html" itemprop="url"><span itemprop="name">SPEAKING DATES</span></a></li>
</ul>
</li>
<li id="menu-item-230" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-230"><a href="../../../faq.html" itemprop="url"><span itemprop="name">FAQ</span></a></li>
<li id="menu-item-19" class="menu-item menu-item-type-post_type menu-item-object-page current_page_parent menu-item-19"><a href="../../index.html" itemprop="url"><span itemprop="name">Blog</span></a></li>
</ul></nav></div></section>
</div></div></header><div class="site-inner"><div class="content-sidebar-wrap"><main class="content"><article class="post-355 post type-post status-publish format-standard category-uncategorized tag-jama entry" itemscope itemtype="http://schema.org/CreativeWork"><header class="entry-header"><h1 class="entry-title" itemprop="headline">Lessons in Outcome Switching: The ERASE Trial</h1> 
<p class="entry-meta"><time class="entry-time" itemprop="datePublished" datetime="2016-03-22T22:52:20+00:00">March 22, 2016</time> - by <span class="entry-author" itemprop="author" itemscope itemtype="http://schema.org/Person"><a href="../../author/aarondale/index.html" class="entry-author-link" itemprop="url" rel="author"><span class="entry-author-name" itemprop="name">Aaron Dale</span></a></span> <span class="entry-comments-link"><a href="index.html#comments">1 Comment</a></span></p></header><div class="entry-content" itemprop="text"><h4><span style="font-weight: 400;">Over 6 weeks </span><span style="color: #0000ff;"><a style="color: #0000ff;" href="../../../team.html"><span style="font-weight: 400;">the COMPare team</span></a></span><span style="font-weight: 400;"> analysed 67 trials in the top 5 medical journals to assess the ongoing prevalence of outcome switching in clinical trials, and to find out why it persists. Our methodology can be found </span><span style="color: #0000ff;"><a style="color: #0000ff;" href="../../../project.html#methodology"><span style="font-weight: 400;">here</span></a></span><span style="font-weight: 400;">. In this series we will be highlighting the salient lessons learned from this process by describing the analysis of several trials in detail. Each study highlights different ways in which outcomes can be misreported, leading to undetected flaws in the evidence presented in clinical trial reports.</span></h4>
<h4><span style="color: #000000;"><span style="font-weight: 400;">Here we describe our coding of the ERASE trial </span><span style="font-weight: 400;">[1]. The context and overview of this study is described in </span><span style="color: #0000ff;"><a style="color: #0000ff;" href="http://jama.jamanetwork.com/article.aspx?articleid=2468877&amp;utm_campaign=articlePDF&amp;utm_medium=articlePDFlink&amp;utm_source=articlePDF&amp;utm_content=jama.2015.14851"><span style="font-weight: 400;">this editorial</span></a></span><span style="font-weight: 400;">. This study was 1 of 13 randomised control trials published in JAMA that we analysed. Of these, 11 contained outcome switching and required a letter of correction. All were rejected by JAMA’s editors; more on that, including full correspondence with JAMA&#8217;s editors, <a href="../../jama-reject-all-correction-letters/index.html">here</a>.</span></span></h4>
<p>&nbsp;</p>
<h4><span style="font-weight: 400; color: #000000;"> Our summary analysis of outcome reporting in the ERASE trial was that:</span></h4>
<h4 style="text-align: center;"><strong><span style="color: #ff0000;"><i>3/3 pre-specified primary outcomes were correctly reported</i></span></strong></h4>
<h4 style="text-align: center;"><strong><span style="color: #ff0000;"><i>21/37 pre-specified secondary outcomes were correctly reported</i></span></strong></h4>
<h4 style="text-align: center;"><strong><span style="color: #ff0000;"><i> 16/37 pre-specified secondary outcomes were not reported at all</i></span></strong></h4>
<h4 style="text-align: center;"><strong><span style="color: #ff0000;"><i> 6 additional outcomes were reported that were not pre-specified</i></span></strong></h4>
<p>&nbsp;</p>
<p style="text-align: center;"><span id="more-355"></span></p>
<p><span style="font-weight: 400; color: #000000;">But what does that mean? We don’t want people to accept our data on trust alone. The whole point of COMPare is that we want transparency about methods and results: that’s why we share all our raw data. But we also want people to be able to understand how this kind of work is done, and why outcome switching matters. So this blog post uses the ERASE trial as a worked example, to show exactly how we assess a trial for misreported outcomes.  </span></p>
<p>&nbsp;</p>
<h2><span style="color: #000000;"><b>Part 1 &#8211; Identifying the pre-specified outcomes</b></span></h2>
<p>&nbsp;</p>
<p><span style="color: #000000;"><span style="font-weight: 400;">As described in our </span><span style="color: #0000ff;"><a style="color: #0000ff;" href="../../../wp-content/uploads/2016/01/COMPare-Protocol-18.5.2016.pdf"><span style="font-weight: 400;">protocol</span></a></span><span style="font-weight: 400;">, the analysis process begins with first identifying the trial commencement date. We then have to find the pre-trial protocol that contains the pre-specified outcomes. If this is not publically available, or is dated after trial commencement, we refer to the online registry to identify pre-specified outcomes. For the ERASE trial, the start date is clearly stated in the abstract as May 17 2010, and version 2 of the protocol, linked directly from the paper, is dated 2009 (Fig. 1).</span></span></p>
<p><img class=" wp-image-356 aligncenter" src="../../../wp-content/uploads/2016/03/figure1-300x236.png" alt="figure1" width="543" height="427" srcset="../../../wp-content/uploads/2016/03/figure1-300x236.png 300w, ../../../wp-content/uploads/2016/03/figure1-768x604.png 768w, ../../../wp-content/uploads/2016/03/figure1.png 785w" sizes="(max-width: 543px) 100vw, 543px" /></p>
<p style="text-align: center;"><span style="color: #000000;"><i><span style="font-weight: 400;">              Figure 1. Dates of trial commencement and protocol submission for ERASE</span></i></span></p>
<p><span style="font-weight: 400; color: #000000;">The outcomes were generally well defined in the protocol, giving the specific variable to be measured, the time point of measurement and the method of measurement. For example, here are the primary outcomes:</span></p>
<p><img class=" wp-image-446 aligncenter" src="../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-23-at-08.36.06-300x106.png" alt="Screen Shot 2016-03-23 at 08.36.06" width="739" height="261" srcset="../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-23-at-08.36.06-300x106.png 300w, ../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-23-at-08.36.06-768x271.png 768w, ../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-23-at-08.36.06.png 894w" sizes="(max-width: 739px) 100vw, 739px" /></p>
<p style="text-align: center;"><em><span style="color: #000000; line-height: 1.5;">F</span></em><i style="color: #000000; line-height: 1.5;">igure 2. Primary outcomes for ERASE, from version 2 of the trial protcol</i></p>
<p><span style="font-weight: 400;">From<span style="color: #000000;"> this we can see that the primary outcomes are maximum walking distance at 1, 6 and 12 months, giving three primary outcomes in total. Reading the rest of the protocol identified 37 secondary outcomes which were entered into </span></span><span style="color: #0000ff;"><a style="color: #0000ff;" href="https://docs.google.com/spreadsheets/d/1eAkim6TDGpep4M2iILGn2wdUywyPD6zY5WCcW8pwBU4/edit#gid=0"><span style="font-weight: 400;">our assessment sheet</span><span style="font-weight: 400;">,</span></a></span><span style="font-weight: 400;"> giving 40 outcomes in total. We will identify each of these pre-specified secondary outcomes in part 2.</span></p>
<p>&nbsp;</p>
<h2><b>Part 2 &#8211; Assessing which pre-specified outcomes were reported</b></h2>
<p>&nbsp;</p>
<p><span style="font-weight: 400; color: #000000;">The next step is to systematically scour the paper to determine which of these pre-specified outcomes were reported. When I originally did the first assessment on this trial, I made screen grabs of the outcomes reported in the paper and totted the findings up at the bottom of a powerpoint presentation, to ease discussion at our weekly meeting where every outcome is checked by the team. Here is an example:</span></p>
<p><img class="alignnone wp-image-359 aligncenter" src="../../../wp-content/uploads/2016/03/figure3-300x225.png" alt="figure3" width="644" height="483" srcset="../../../wp-content/uploads/2016/03/figure3-300x225.png 300w, ../../../wp-content/uploads/2016/03/figure3.png 710w" sizes="(max-width: 644px) 100vw, 644px" /></p>
<p style="text-align: center;"><span style="color: #000000;"><i><span style="font-weight: 400;">Figure 3. Example of how trial analysis was communicated to the COMPare team</span></i></span></p>
<p>&nbsp;</p>
<p><span style="font-weight: 400; color: #000000;">So let’s go through the outcomes reported in this trial. As we do so we will tot up the number of pre-specified outcomes reported and omitted in a summary table.</span></p>
<p><span style="color: #000000; line-height: 1.5;">First of all, the primary outcomes of maximum walking distance at 1, 6 and 12 months are clearly reported in Table 2 (Fig. 4).</span></p>
<p><img class=" wp-image-426 aligncenter" src="../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-23-at-08.05.14-300x106.png" alt="Screen Shot 2016-03-23 at 08.05.14" width="664" height="235" srcset="../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-23-at-08.05.14-300x106.png 300w, ../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-23-at-08.05.14.png 685w" sizes="(max-width: 664px) 100vw, 664px" /></p>
<p style="text-align: center;"><span style="color: #000000;"><i><span style="font-weight: 400;">Figure 4. Primary outcomes 1-3 for ERASE, clearly reported in the trial publication</span></i></span></p>
<p style="text-align: center;"><img class="wp-image-388 aligncenter" src="../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-22-at-21.53.32-300x57.png" alt="Screen Shot 2016-03-22 at 21.53.32" width="727" height="138" srcset="../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-22-at-21.53.32-300x57.png 300w, ../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-22-at-21.53.32.png 611w" sizes="(max-width: 727px) 100vw, 727px" /></p>
<p>&nbsp;</p>
<p><span style="font-weight: 400; color: #000000;">Now for the secondary outcomes. The first noted in the protocol were preference-based utility measurements EQ-5D and “Rating Scale”, each at three time points: that makes 6 outcomes in total (Fig. 5) </span></p>
<p><img class=" wp-image-427 aligncenter" src="../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-23-at-08.07.03-300x110.png" alt="Screen Shot 2016-03-23 at 08.07.03" width="704" height="258" srcset="../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-23-at-08.07.03-300x110.png 300w, ../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-23-at-08.07.03-768x283.png 768w, ../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-23-at-08.07.03.png 896w" sizes="(max-width: 704px) 100vw, 704px" /></p>
<p style="text-align: center;"><span style="color: #000000;"><i><span style="font-weight: 400;">Figure 5. Pre-specified secondary outcomes 1-6 for ERASE, from version 2 of the protocol</span></i></span></p>
<p>&nbsp;</p>
<p><span style="font-weight: 400; color: #000000;">We found Rating Scale in Table 3 (called “Rating Score” in the paper &#8211; Fig. 6) but were unable to find any reference to EQ-5D in the paper. </span></p>
<p><img class=" wp-image-428 aligncenter" src="../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-23-at-08.09.22-300x15.png" alt="Screen Shot 2016-03-23 at 08.09.22" width="620" height="31" srcset="../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-23-at-08.09.22-300x15.png 300w, ../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-23-at-08.09.22.png 688w" sizes="(max-width: 620px) 100vw, 620px" /> <img class=" wp-image-429 aligncenter" src="../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-23-at-08.09.39-300x53.png" alt="Screen Shot 2016-03-23 at 08.09.39" width="617" height="109" srcset="../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-23-at-08.09.39-300x53.png 300w, ../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-23-at-08.09.39.png 686w" sizes="(max-width: 617px) 100vw, 617px" /></p>
<p style="text-align: center;"><span style="color: #000000;"><i><span style="font-weight: 400;">Figure 6. Analysis of pre-specified secondary outcomes 1-6  in ERASE. Rating Score (Scale) but not EQ-5D were reported.</span></i></span></p>
<p style="text-align: center;"><img class="alignnone wp-image-396" src="../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-22-at-21.54.52-300x58.png" alt="Screen Shot 2016-03-22 at 21.54.52" width="740" height="143" srcset="../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-22-at-21.54.52-300x58.png 300w, ../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-22-at-21.54.52.png 612w" sizes="(max-width: 740px) 100vw, 740px" /></p>
<p>&nbsp;</p>
<p><span style="font-weight: 400; color: #000000;">Secondary outcomes 7-18 were SF-36 and VascuQol quality of life score as detailed at the top of figure 7, at multiple timepoints. </span></p>
<p><img class=" wp-image-430 aligncenter" src="../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-23-at-08.11.38-300x91.png" alt="Screen Shot 2016-03-23 at 08.11.38" width="726" height="220" srcset="../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-23-at-08.11.38-300x91.png 300w, ../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-23-at-08.11.38-768x233.png 768w, ../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-23-at-08.11.38.png 914w" sizes="(max-width: 726px) 100vw, 726px" /></p>
<p><img class=" wp-image-431 aligncenter" src="../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-23-at-08.12.08-238x300.png" alt="Screen Shot 2016-03-23 at 08.12.08" width="674" height="850" srcset="../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-23-at-08.12.08-238x300.png 238w, ../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-23-at-08.12.08.png 401w" sizes="(max-width: 674px) 100vw, 674px" /></p>
<p style="text-align: center;"><span style="color: #000000;"><i><span style="font-weight: 400;">Figure 7. Pre-specified secondary outcomes 7-18 in ERASE. Protocol entry above and publication table below. Green boxes indicate outcomes that were pre-specified. Red boxes indicate outcomes that were not pre-specified.</span></i></span></p>
<p><span style="color: #000000;"><span style="color: #0000ff;"><a style="color: #0000ff;" href="http://www.sf-36.org/tools/SF36.shtml"><span style="font-weight: 400;">SF-36</span></a></span><span style="font-weight: 400;"> is a short form health survey questionnaire composed of 36 questions. These questions are divided into 4 physical domains (“General Health”, “Physical Functioning”, “Bodily Pain” and “Physical Role Functioning”) and 4 mental domains (”Vitality”, “Emotional Role Functioning”, “Mental Health” and “Social Functioning”). Each of these domains can be pre-specified independently. The ERASE protocol specifically pre-specifies physical-functioning, social-functioning and physical-role-functioning (3 outcomes at 3 time points, giving 9 outcomes total). Of these, they reported physical-role-functioning and physical-functioning, omitted social functioning, and additionally report bodily pain and general health. No justification was given for the additional reporting of these two subscales in the paper itself &#8211; more on this in Part 3.</span></span></p>
<p><span style="font-weight: 400; color: #000000;">Secondary outcomes 16-18 (VascuQoL) were correctly reported (Fig. 7). So, we now have&#8230;</span></p>
<p style="text-align: center;"><img class="alignnone wp-image-397" src="../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-22-at-21.55.24-300x57.png" alt="Screen Shot 2016-03-22 at 21.55.24" width="747" height="142" srcset="../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-22-at-21.55.24-300x57.png 300w, ../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-22-at-21.55.24.png 611w" sizes="(max-width: 747px) 100vw, 747px" /></p>
<p><span style="font-weight: 400; color: #000000;">Secondary outcomes 19-27 were the pain free walking distance and the ABI at rest and after exercise at 1, 6 and 12 months. All of these were correctly reported (Fig. 8)</span></p>
<p><img class=" wp-image-432 aligncenter" src="../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-23-at-08.16.53-300x55.png" alt="Screen Shot 2016-03-23 at 08.16.53" width="781" height="143" srcset="../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-23-at-08.16.53-300x55.png 300w, ../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-23-at-08.16.53-768x142.png 768w, ../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-23-at-08.16.53.png 917w" sizes="(max-width: 781px) 100vw, 781px" /></p>
<p><img class=" wp-image-433 aligncenter" src="../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-23-at-08.17.14-300x265.png" alt="Screen Shot 2016-03-23 at 08.17.14" width="710" height="628" srcset="../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-23-at-08.17.14-300x265.png 300w, ../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-23-at-08.17.14.png 533w" sizes="(max-width: 710px) 100vw, 710px" /></p>
<p style="text-align: center;"><span style="color: #000000;"><i><span style="font-weight: 400;">Figure 8. Pre-specified secondary outcomes 19-27 in ERASE. <i><span style="font-weight: 400;">Protocol entry above, relevant text in publication below.</span></i></span></i></span></p>
<p><img class=" wp-image-398 aligncenter" src="../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-22-at-21.55.58-300x58.png" alt="Screen Shot 2016-03-22 at 21.55.58" width="781" height="151" srcset="../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-22-at-21.55.58-300x58.png 300w, ../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-22-at-21.55.58.png 610w" sizes="(max-width: 781px) 100vw, 781px" /></p>
<p>&nbsp;</p>
<p><span style="font-weight: 400; color: #000000;">Secondary outcomes 28-30 were “clinical success”. This was well defined in the protocol (Fig. 9). However, no mention of this was given in the publication nor was its omission justified. To be sure we hadn’t missed this, in addition to both assessors thoroughly reviewing the manuscript with this outcome in mind, three authors scanned key words “clinical” “success” “Rutherford”, “Gardner” and this revealed nothing relevant to this outcome. The authors reported technical success rates for endovascular revascularisation but we did not deem this to be equivalent to the clearly defined pre-specified outcome of clinical success. This takes our running total of unreported outcomes up to 9.</span></p>
<p><img class=" wp-image-434 aligncenter" src="../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-23-at-08.20.38-300x54.png" alt="Screen Shot 2016-03-23 at 08.20.38" width="727" height="131" srcset="../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-23-at-08.20.38-300x54.png 300w, ../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-23-at-08.20.38-768x139.png 768w, ../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-23-at-08.20.38.png 859w" sizes="(max-width: 727px) 100vw, 727px" /></p>
<p style="text-align: center;"><span style="color: #000000;"><i><span style="font-weight: 400;">Figure 9. Pre-specified secondary outcomes 28-30 in the ERASE protocol, version 2</span></i></span></p>
<p style="text-align: center;"><img class="alignnone wp-image-399" src="../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-22-at-21.56.26-300x57.png" alt="Screen Shot 2016-03-22 at 21.56.26" width="758" height="144" srcset="../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-22-at-21.56.26-300x57.png 300w, ../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-22-at-21.56.26.png 611w" sizes="(max-width: 758px) 100vw, 758px" /></p>
<p><span style="font-weight: 400; color: #000000;">Secondary outcome 31 related to cost-effectiveness of the procedure (Fig. 10). This was not reported in the publication but a specific statement is made that this data will be reported elsewhere. This is widely accepted as best practice, and an important illustration of a wider recurring theme: outcomes do sometimes change between the commencement and conclusion of a trial, and there may be good reasons for leaving something unreported, or adding in a novel outcome; however it is important that this is openly declared and discussed in the paper. Consistent with CONSORT guidelines, widely accepted best practice, and our shared operations manual we therefore removed this outcome from our denominator, so our summary statistics remain unchanged.  </span></p>
<p><img class=" wp-image-435 aligncenter" src="../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-23-at-08.22.01-300x210.png" alt="Screen Shot 2016-03-23 at 08.22.01" width="578" height="404" srcset="../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-23-at-08.22.01-300x210.png 300w, ../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-23-at-08.22.01-768x538.png 768w, ../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-23-at-08.22.01.png 901w" sizes="(max-width: 578px) 100vw, 578px" /></p>
<p><img class=" wp-image-437 aligncenter" src="../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-23-at-08.24.47-300x48.png" alt="Screen Shot 2016-03-23 at 08.24.47" width="425" height="68" srcset="../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-23-at-08.24.47-300x48.png 300w, ../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-23-at-08.24.47.png 461w" sizes="(max-width: 425px) 100vw, 425px" /></p>
<p style="text-align: center;"><span style="color: #000000;"><i><span style="font-weight: 400;">Figure 10. Pre-specified secondary outcome “therapeutic and total costs”  in ERASE. Protocol entry above, relevant text from the report&#8217;s introduction below.</span></i></span></p>
<p><img class="wp-image-400 aligncenter" src="../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-22-at-21.58.24-300x59.png" alt="Screen Shot 2016-03-22 at 21.58.24" width="814" height="160" srcset="../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-22-at-21.58.24-300x59.png 300w, ../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-22-at-21.58.24.png 609w" sizes="(max-width: 814px) 100vw, 814px" /></p>
<p>&nbsp;</p>
<p><span style="font-weight: 400; color: #000000;">The risk of cardiovascular disease was pre-specified as an outcome as shown in figure 12. We interpreted this as a single risk factor score (a composite of Euro SCORE and Framingham CVD risk scores), to be reported at 6 and 12 months, giving secondary outcomes 31-32. No reference to any of these scores were given in the text. No justification was given for these omissions. This takes the number of unreported outcomes to 11.</span></p>
<p><img class=" wp-image-440 aligncenter" src="../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-23-at-08.26.41-300x48.png" alt="Screen Shot 2016-03-23 at 08.26.41" width="682" height="109" srcset="../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-23-at-08.26.41-300x48.png 300w, ../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-23-at-08.26.41-768x123.png 768w, ../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-23-at-08.26.41.png 862w" sizes="(max-width: 682px) 100vw, 682px" /><img class=" wp-image-439 aligncenter" src="../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-23-at-08.25.42-300x26.png" alt="Screen Shot 2016-03-23 at 08.25.42" width="682" height="59" srcset="../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-23-at-08.25.42-300x26.png 300w, ../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-23-at-08.25.42-768x67.png 768w, ../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-23-at-08.25.42.png 791w" sizes="(max-width: 682px) 100vw, 682px" /></p>
<p style="text-align: center;"><span style="color: #000000;"><i><span style="font-weight: 400;">Figure 11. Pre-specified secondary outcomes 31-32 in the ERASE protocol version 2</span></i></span></p>
<p><img class="wp-image-401 aligncenter" src="../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-22-at-21.58.53-300x58.png" alt="Screen Shot 2016-03-22 at 21.58.53" width="755" height="146" srcset="../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-22-at-21.58.53-300x58.png 300w, ../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-22-at-21.58.53.png 610w" sizes="(max-width: 755px) 100vw, 755px" /></p>
<p><span style="font-weight: 400; color: #000000;"><br />
Medication use at 6 and 12 months was pre-specified as an outcome (Fig. 13). These outcomes (one measure at two timepoints) were not reported or mentioned in the text of the publication, taking the total number of unreported outcomes to 13.</span></p>
<p style="text-align: center;"><img class=" wp-image-442 aligncenter" src="../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-23-at-08.28.31-300x39.png" alt="Screen Shot 2016-03-23 at 08.28.31" width="730" height="95" srcset="../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-23-at-08.28.31-300x39.png 300w, ../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-23-at-08.28.31-768x99.png 768w, ../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-23-at-08.28.31.png 887w" sizes="(max-width: 730px) 100vw, 730px" /><span style="color: #000000;"><i><span style="font-weight: 400;"> Figure 12. Pre-specified secondary outcomes 33-34 in the ERASE protocol version 2</span></i></span></p>
<p><img class="wp-image-402 aligncenter" src="../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-22-at-21.59.25-300x59.png" alt="Screen Shot 2016-03-22 at 21.59.25" width="793" height="156" srcset="../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-22-at-21.59.25-300x59.png 300w, ../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-22-at-21.59.25.png 609w" sizes="(max-width: 793px) 100vw, 793px" /></p>
<p>&nbsp;</p>
<p><span style="font-weight: 400; color: #000000;">Adverse events were pre-specified as shown in figure 14. It is unclear exactly how these were to be reported from this wording, but we would expect a percentage figure for each adverse event pre-specified at each time point. Some reference to these events are made in the free text (e.g. Fig. 15), however our view was that this was inconsistent with the pre-specification.</span></p>
<p><img class=" wp-image-443 aligncenter" src="../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-23-at-08.29.17-300x52.png" alt="Screen Shot 2016-03-23 at 08.29.17" width="703" height="122" srcset="../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-23-at-08.29.17-300x52.png 300w, ../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-23-at-08.29.17-768x134.png 768w, ../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-23-at-08.29.17.png 872w" sizes="(max-width: 703px) 100vw, 703px" /></p>
<p style="text-align: center;"><span style="color: #000000;"><i><span style="font-weight: 400;">Figure 13. Pre-specified secondary outcomes 35-37 in the ERASE protocol version 2</span></i></span></p>
<p><img class=" wp-image-444 aligncenter" src="../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-23-at-08.30.37-300x165.png" alt="Screen Shot 2016-03-23 at 08.30.37" width="409" height="225" srcset="../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-23-at-08.30.37-300x165.png 300w, ../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-23-at-08.30.37.png 475w" sizes="(max-width: 409px) 100vw, 409px" /> <img class=" wp-image-445 aligncenter" src="../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-23-at-08.30.52-300x217.png" alt="Screen Shot 2016-03-23 at 08.30.52" width="411" height="297" srcset="../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-23-at-08.30.52-300x217.png 300w, ../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-23-at-08.30.52.png 482w" sizes="(max-width: 411px) 100vw, 411px" /></p>
<p style="text-align: center;"><span style="color: #000000;"><i><span style="font-weight: 400;">Figure 14. Incomplete reference to secondary outcomes 35-37 in the free text of the ERASE report</span></i></span></p>
<p><img class="wp-image-403 aligncenter" src="../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-22-at-22.00.15-300x58.png" alt="Screen Shot 2016-03-22 at 22.00.15" width="776" height="150" srcset="../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-22-at-22.00.15-300x58.png 300w, ../../../wp-content/uploads/2016/03/Screen-Shot-2016-03-22-at-22.00.15.png 611w" sizes="(max-width: 776px) 100vw, 776px" /></p>
<p><span style="font-weight: 400; color: #000000;">Well done for making it through that. Hopefully you’ll be able to see that this is a simple process, and should be well within the capabilities of an editorial team to review.</span></p>
<p>&nbsp;</p>
<h2><span style="color: #000000;"><b>Part 3 &#8211; Correcting the record</b></span></h2>
<p>&nbsp;</p>
<p><span style="font-weight: 400; color: #000000;">Having completed our analysis the next stage in the COMPare process is to decide if a letter is warranted to correct the record, and if so draft and submit it. Our summary analysis of outcome reporting in the ERASE trial was that:</span></p>
<p style="text-align: center;"><strong><span style="color: #ff0000;"><i>3/3 pre-specified primary outcomes were correctly reported</i></span></strong></p>
<p style="text-align: center;"><strong><span style="color: #ff0000;"><i>21/37 pre-specified secondary outcomes were correctly reported</i></span></strong></p>
<p style="text-align: center;"><strong><span style="color: #ff0000;"><i> 16/37 pre-specified secondary outcomes were not reported at all</i></span></strong></p>
<p style="text-align: center;"><strong><span style="color: #ff0000;"><i> 6 additional outcomes were reported that were not pre-specified</i></span></strong></p>
<p><span style="color: #000000;"><span style="font-weight: 400;">We therefore wrote </span><span style="color: #0000ff;"><a style="color: #0000ff;" href="https://drive.google.com/file/d/0B7EgEnbh0CtLSlpYal9QWjBZRVk/view"><span style="font-weight: 400;">this letter</span></a></span><span style="font-weight: 400;"> to JAMA to highlight the discrepancies, following our standard format for letters to journals. As with all our letters, JAMA declined to publish it, on which more <a href="../../jama-reject-all-correction-letters/index.html">here</a>. As a result of JAMA rejecting this correction letter, readers of the journal will be unaware that this trial was misreported on the pages of JAMA: this is especially the case if readers take JAMA’s public commitment to good practice in reporting clinical trials at face value and assume, reasonably, that JAMA has checked all trials that they publish for outcome switching.  </span></span></p>
<p><span style="font-weight: 400; color: #000000;">A key point raised in this trial is the selective reporting of quality of life subscales. Specifically, in this trial 3 of 8 subscales of the SF-36 were pre-specified, 2 of 3 of these were reported, and an additional 2 subscales that were not pre-specified were also reported. The trialists also failed to report another pre-specified quality of life scale, the EQ-5D. The laxity of reporting of quality of life subscales, if left unchecked, opens the doors for manipulation of trial data by those who may wish to hide unflattering results. In this trial one could, for example, imagine the failure to report the social functioning subscale of SF-36 may hide an effect that would be of interest to a clinician seeking to counsel a patient on the potential drawbacks of endovascular revascularisation for intermittent claudication. On this we should be clear: we certainly don’t believe that every trialist engaging in outcome switching is deliberately massaging their figures; however, the culture of permissiveness around this issue gives cover to those who are manipulating data. </span></p>
<p><span style="font-weight: 400; color: #000000;">In addition to quality of life subscales we find it odd that “clinical success”, an outcome measure that is key to the aims of the trial, would not be reported. Furthermore, “medication use” was not reported despite being pre-specified as an outcome. In both cases there was no mention that these outcomes were pre-specified anywhere in the text, and the reader is therefore unaware these outcomes were ever under consideration. This makes it very easy for unflattering results to go unreported and unnoticed in the medical literature, robbing patients and clinicians of important evidence which could have a direct impact on clinical decision making. Trials are extremely expensive and administratively cumbersome research projects, conducted for one reason: to exclude bias. After spending all this money on running a trial, it makes no sense for those biases to be re-introduced at the end of the process by permitting selective outcome reporting. Reporting all outcomes correctly reduces bias, it meets the core aim of the trial, and it costs nothing.   </span></p>
<p><span style="font-weight: 400; color: #000000;">We hope this worked example helps to illustrate why outcome switching is important, how it can be identified, and how unhelpful it is that journals not only fail to manage the problem themselves, but also reject attempts to correct the record after they have permitted misreporting.</span></p>
<p>&nbsp;</p>
<p><strong><span style="color: #000000;">Aaron Dale, Henry Drysdale, Ben Goldacre, Carl Heneghan on behalf of the COMPare team</span></strong></p>
<p><strong><span style="color: #000000;">March 2016</span></strong></p>
<p>&nbsp;</p>
<p><span style="text-decoration: underline;"><span style="color: #000000;"><b><i>References:</i></b></span></span></p>
<p><span style="font-weight: 400; color: #000000;">[1] Fakhry F, Spronk S, van der Laan L, et al. Endovascular Revascularization and Supervised Exercise for Peripheral Artery Disease and Intermittent Claudication: A Randomized Clinical Trial.  JAMA. 2015;314(18):1936-1944.</span></p>
<p>&nbsp;</p>
<div class="social"><a class="synved-social-button synved-social-button-share synved-social-size-48 synved-social-resolution-normal synved-social-provider-facebook nolightbox" data-provider="facebook" target="_blank" rel="nofollow" title="Share on Facebook" href="http://www.facebook.com/sharer.php?u=http%3A%2F%2Fcompare-trials.org%2Fblog%2Flessons%2Ferase&#038;t=Lessons%20in%20Outcome%20Switching%3A%20The%20ERASE%20Trial&#038;s=100&#038;p&#091;url&#093;=http%3A%2F%2Fcompare-trials.org%2Fblog%2Flessons%2Ferase&#038;p&#091;images&#093;&#091;0&#093;=http%3A%2F%2Fcompare-trials.org%2Fwp-content%2Fuploads%2F2016%2F03%2Ffigure1-300x236.png&#038;p&#091;title&#093;=Lessons%20in%20Outcome%20Switching%3A%20The%20ERASE%20Trial" style="font-size: 0px; width:48px;height:48px;margin:0;margin-bottom:5px;margin-right:5px;"><img alt="Facebook" title="Share on Facebook" class="synved-share-image synved-social-image synved-social-image-share" width="48" height="48" style="display: inline; width:48px;height:48px; margin: 0; padding: 0; border: none; box-shadow: none;" src="../../../wp-content/plugins/social-media-feather/synved-social/image/social/regular/48x48/facebook.png" /></a><a class="synved-social-button synved-social-button-share synved-social-size-48 synved-social-resolution-normal synved-social-provider-twitter nolightbox" data-provider="twitter" target="_blank" rel="nofollow" title="Share on Twitter" href="https://twitter.com/intent/tweet?url=http%3A%2F%2Fcompare-trials.org%2Fblog%2Flessons%2Ferase&#038;text=COMPare%3A%20Tracking%20switched%20outcomes%20in%20clinical%20trials" style="font-size: 0px; width:48px;height:48px;margin:0;margin-bottom:5px;"><img alt="twitter" title="Share on Twitter" class="synved-share-image synved-social-image synved-social-image-share" width="48" height="48" style="display: inline; width:48px;height:48px; margin: 0; padding: 0; border: none; box-shadow: none;" src="../../../wp-content/plugins/social-media-feather/synved-social/image/social/regular/48x48/twitter.png" /></a><a class="synved-social-button synved-social-button-share synved-social-size-48 synved-social-resolution-hidef synved-social-provider-facebook nolightbox" data-provider="facebook" target="_blank" rel="nofollow" title="Share on Facebook" href="http://www.facebook.com/sharer.php?u=http%3A%2F%2Fcompare-trials.org%2Fblog%2Flessons%2Ferase&#038;t=Lessons%20in%20Outcome%20Switching%3A%20The%20ERASE%20Trial&#038;s=100&#038;p&#091;url&#093;=http%3A%2F%2Fcompare-trials.org%2Fblog%2Flessons%2Ferase&#038;p&#091;images&#093;&#091;0&#093;=http%3A%2F%2Fcompare-trials.org%2Fwp-content%2Fuploads%2F2016%2F03%2Ffigure1-300x236.png&#038;p&#091;title&#093;=Lessons%20in%20Outcome%20Switching%3A%20The%20ERASE%20Trial" style="font-size: 0px; width:48px;height:48px;margin:0;margin-bottom:5px;margin-right:5px;"><img alt="Facebook" title="Share on Facebook" class="synved-share-image synved-social-image synved-social-image-share" width="48" height="48" style="display: inline; width:48px;height:48px; margin: 0; padding: 0; border: none; box-shadow: none;" src="../../../wp-content/plugins/social-media-feather/synved-social/image/social/regular/96x96/facebook.png" /></a><a class="synved-social-button synved-social-button-share synved-social-size-48 synved-social-resolution-hidef synved-social-provider-twitter nolightbox" data-provider="twitter" target="_blank" rel="nofollow" title="Share on Twitter" href="https://twitter.com/intent/tweet?url=http%3A%2F%2Fcompare-trials.org%2Fblog%2Flessons%2Ferase&#038;text=COMPare%3A%20Tracking%20switched%20outcomes%20in%20clinical%20trials" style="font-size: 0px; width:48px;height:48px;margin:0;margin-bottom:5px;"><img alt="twitter" title="Share on Twitter" class="synved-share-image synved-social-image synved-social-image-share" width="48" height="48" style="display: inline; width:48px;height:48px; margin: 0; padding: 0; border: none; box-shadow: none;" src="../../../wp-content/plugins/social-media-feather/synved-social/image/social/regular/96x96/twitter.png" /></a></div></div><footer class="entry-footer"><p class="entry-meta"><span class="entry-tags">Tagged With: <a href="../../tag/jama/index.html" rel="tag">jama</a></span></p></footer></article><section class="author-box" itemprop="author" itemscope itemtype="http://schema.org/Person"><img alt='' src='http://0.gravatar.com/avatar/fa2d92d49b1f0ea0cee567ae635c7e28?s=176&#038;d=mm&#038;r=g' srcset='http://0.gravatar.com/avatar/fa2d92d49b1f0ea0cee567ae635c7e28?s=352&amp;d=mm&amp;r=g 2x' class='avatar avatar-176 photo' height='176' width='176' /><h1 class="author-box-title">About <span itemprop="name">Aaron Dale</span></h1><div class="author-box-content" itemprop="description"></div></section><div class="after-entry widget-area"><section id="search-3" class="widget widget_search"><div class="widget-wrap"><form class="search-form" itemprop="potentialAction" itemscope itemtype="http://schema.org/SearchAction" method="get" action="../../../index.html" role="search"><meta itemprop="target" content="http://compare-trials.org/?s={s}"/><input itemprop="query-input" type="search" name="s" placeholder="Search this website &#x2026;" /><input type="submit" value="Search"  /></form></div></section>
</div><div class="entry-comments" id="comments"><h3>Comments</h3><ol class="comment-list">
	<li class="comment even thread-even depth-1" id="comment-460">
	<article itemprop="comment" itemscope itemtype="http://schema.org/Comment">

		
		<header class="comment-header">
			<p class="comment-author" itemprop="author" itemscope itemtype="http://schema.org/Person">
				<img alt='' src='http://0.gravatar.com/avatar/08fe0a86319b12ff4db3d740248a5158?s=120&#038;d=mm&#038;r=g' srcset='http://0.gravatar.com/avatar/08fe0a86319b12ff4db3d740248a5158?s=240&amp;d=mm&amp;r=g 2x' class='avatar avatar-120 photo' height='120' width='120' /><span itemprop="name"><a href="http://www.swissnephro.org" class="comment-author-link" rel="external nofollow" itemprop="url">Florian Buchkremer (@swissnephro)</a></span> <span class="says">says</span>			</p>

			<p class="comment-meta"><time class="comment-time" datetime="2016-03-23T18:30:28+00:00" itemprop="datePublished"><a href="index.html#comment-460" class="comment-time-link" itemprop="url">March 23, 2016 at 6:30 pm</a></time></p>		</header>

		<div class="comment-content" itemprop="text">
			
			<p>Do you contact the authors directly with your concerns? Even if  JAMA and other journals are not doing their job properly, the authors should be given an opportunity to address your reservations!</p>
		</div>

		<div class="comment-reply"><a rel='nofollow' class='comment-reply-link' href='../erase%3Freplytocom=460.html#respond' onclick='return addComment.moveForm( "comment-460", "460", "respond", "355" )' aria-label='Reply to Florian Buchkremer (@swissnephro)'>Reply</a></div>
		
	</article>
	</li><!-- #comment-## -->
</ol></div>				<div id="respond" class="comment-respond">
			<h3 id="reply-title" class="comment-reply-title">Leave a Reply <small><a rel="nofollow" id="cancel-comment-reply-link" href="index.html#respond" style="display:none;">Cancel reply</a></small></h3>				<form action="http://compare-trials.org/wp-comments-post.php" method="post" id="commentform" class="comment-form" novalidate>
					<p class="comment-notes"><span id="email-notes">Your email address will not be published.</span> Required fields are marked <span class="required">*</span></p><p class="comment-form-comment"><label for="comment">Comment</label> <textarea id="comment" name="comment" cols="45" rows="8" maxlength="65525" aria-required="true" required="required"></textarea></p><p class="comment-form-author"><label for="author">Name <span class="required">*</span></label> <input id="author" name="author" type="text" value="" size="30" maxlength="245" aria-required='true' required='required' /></p>
<p class="comment-form-email"><label for="email">Email <span class="required">*</span></label> <input id="email" name="email" type="email" value="" size="30" maxlength="100" aria-describedby="email-notes" aria-required='true' required='required' /></p>
<p class="comment-form-url"><label for="url">Website</label> <input id="url" name="url" type="url" value="" size="30" maxlength="200" /></p>
<p class="form-submit"><input name="submit" type="submit" id="submit" class="submit" value="Post Comment" /> <input type='hidden' name='comment_post_ID' value='355' id='comment_post_ID' />
<input type='hidden' name='comment_parent' id='comment_parent' value='0' />
</p><p style="display: none;"><input type="hidden" id="akismet_comment_nonce" name="akismet_comment_nonce" value="427968f89e" /></p><p style="display: none;"><input type="hidden" id="ak_js" name="ak_js" value="208"/></p>				</form>
					</div><!-- #respond -->
		</main></div></div><div class="footer-widgets"><div class="wrap"><div class="footer-widgets-1 widget-area"><section id="text-2" class="widget widget_text"><div class="widget-wrap"><h4 class="widget-title widgettitle">How to cite us</h4>
			<div class="textwidget"><p>Prior to publication of the first paper on COMPare, please cite this project as:</p>
<p><em>The COMPare Trials Project.</em> Goldacre B, Drysdale H, Powell-Smith A, et al. www.COMPare-trials.org, 2016.</p>
<p>Or alternatively:</p>
<p><em>The COMPare Trials Project.</em> Ben Goldacre, Henry Drysdale, Anna Powell-Smith, Aaron Dale, Ioan Milosevic, Eirion Slade, Philip Hartley, Cicely Marston, Kamal Mahtani, Carl Heneghan. www.COMPare-trials.org, 2016.</p>
</div>
		</div></section>
</div></div></div><footer class="site-footer" itemscope itemtype="http://schema.org/WPFooter"><div class="wrap"><span class="logos">
<a href="http://www.ox.ac.uk"><img src="../../../wp-content/uploads/2016/01/oxford_logo.png" alt="University of Oxford logo" height='40'/></a>
<a href="http://www.phc.ox.ac.uk"><img src="../../../wp-content/uploads/2016/01/nuffield_logo.png" alt="Nuffield Department of Primary Care Health Sciences logo" height='40'/></a>
<a href="http://www.cebm.net/"><img src="../../../wp-content/uploads/2016/01/cebm_logo.png" alt="Centre for Evidence-Based Medicine logo" height='40'/></a>
</span>

<p>
Copyright &#x000A9;&nbsp;2019 &middot; <a href="https://ebmdatalab.net">EBM Data Lab</a>
</p></div></footer></div><script type="text/javascript" src="https://cdn.datatables.net/s/dt/dt-1.10.10,fh-3.1.0,r-2.0.0/datatables.min.js"></script>
<script src="../../../wp-content/uploads/2016/01/tabletop.js"></script>
<script src="../../../wp-content/uploads/2016/01/countUp.js"></script>
<script src="../../../wp-content/uploads/2016/01/all.js"></script><script type='text/javascript' src='../../../wp-content/plugins/akismet/_inc/form.js%3Fver=3.2'></script>
<script type='text/javascript' src='../../../wp-content/plugins/wp-show-more/wpsm-script.js%3Fver=1.0.1'></script>
<script type='text/javascript' src='../../../wp-includes/js/comment-reply.min.js%3Fver=4.6.16'></script>
<script type='text/javascript' src='../../../wp-content/plugins/easy-twitter-feed-widget/lib/js/widget-easy-twitter-feed-widget.js%3Fver=1.0'></script>
<script type='text/javascript' src='../../../wp-includes/js/wp-embed.min.js%3Fver=4.6.16'></script>
</body></html>
